The laboratory of Medical Biology of Tours University Hospital is labeled Reference Medical Biology Laboratory (Laboratoire de Biologie Médicale de Référence) for the Therapeutic Drug Monitoring (TDM) of monoclonal antibodies (2021-2026, decree published by the Ministry of Health in July 15, 2021). It is the only french laboratory with this title. A presentation and a directory of LBMRs (in French) is available on the website of French Ministry of Health.

Serum concentration of monoclonal antibodies varies from patient to patient, even when their dosage is adapted to weight. This is partly explained by the activity of the treated disease. In addition, there is a relationship between serum concentration of monoclonal antibodies and their efficacy and, in certain cases, between their serum concentration and their adverse effects.

The residual serum concentration of monoclonal antibodies, measured just before an injection, is therefore a biomarker of their efficacy and allows dosage personalization. This is the principle of therapeutic drug monitoring.

The medical biology analyses listed below are based on ELISA techniques developed and validated in the laboratory of Pharmacology-Toxicology of Tours University Hospital, with the help of the Pilot centre for Therapeutic Antibody Monitoring (PiTAM) (Centre Pilote de suivi Biologique des traitements par Anticorps, CePiBAc). These analyses are performed in the environment of the Laboratory of Medical Biology of Tours University Hospital, CHRU de Tours, which is accredited by COFRAC according to standard NF EN ISO 15189 (accreditation n° 9-3537. scope and sites available on www.cofrac.fr).

Antibodies or fusion proteins* whose serum concentrations are measured and interpreted: 

• adalimumab (Humira® and biosimilars) - Desvignes C et al. Bioanalysis 2015

• atezolizumab (Tecentriq®)

• basiliximab (Simulect®) - Thibault G et al. Transpl Int 2016

• bevacizumab (Avastin® and biosimilars) - Ternant D et al. Ther Drug Monit 2010

• cetuximab (Erbitux®) - Cézé N et al. Ther Drug Monit 2009

• eculizumab (Soliris®) - Passot C et al. Bioanalysis 2017

• etanercept* (Enbrel®)

• infliximab (Remicade® and biosimilars) - Ternant D et al. Ther Drug Monit 2006

• nivolumab (Opdivo®)

• panitumumab (Vectibix®) - Desvignes C et al. Bioanalysis 2018

• pembrolizumab (Keytruda®) 

• ramucirumab (Cyramza®) - Desvignes C et al. Bioanalysis 2021

• rituximab (Mabthera® and biosimilars) - Daydé D et al. Blood 2009

• tocilizumab (Roactemra®)

• trastuzumab (Herceptin® and biosimilars) - Bernadou G et al. Br J Clin Pharmacol 2016

• vedolizumab (Entyvio®)

Analyses in development: 

• (will soon be indicated)

If you need an analysis to be performed:

• For patient care: Please go the list of analyses (Manuel de prélèvement - in French) of Tours University Hospital and download the request form. 

• For a biomedical research project: Please go to the CePiBAc page (Centre Pilote de suivi Biologique des traitements par Anticorps - in French)

More information : Team - e-mails (in French)

Our networks are listed on the homepage

Last update: May 25th, 2023